Abstract
Helicobacter pylori , a bacterium that lives in the acidic environment of the stomach, was the third leading cause of cancer deaths globally in 2020. The 2017 American College of Gastroenterology guideline recommends the use of antibiotics, proton pump inhibitors, and (in certain cases) bismuth to treat H pylori . In 2022, vonoprazan-containing regimens, which exhibited noninferiority to and superiority over lansoprazole triple therapy, were approved for H pylori treatment. Although not yet included in the guideline, vonoprazan-containing regimens are a promising alternative because of their efficacy and relative ease of administration. Successful H pylori eradication relies on patient -specific treatment, adherence, and proactive management of antibiotic resistance that comprehends the evolving landscape of therapeutic strategies.